Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyadic InternationalDYAI +21.49%37 Days Payable is 110.15 as of Mar. 2026, which is 44% below its 10-year median of 196.44. GuruFocus rates DYAI with a GF Score™ of 37/100 and a GF Value™ of $0.74 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 702 Biotechnology companies, Dyadic International ranks worse than 50.57% on this metric.
The historical rank and industry rank for Dyadic International's Days Payable or its related term are showing as below:
DYAI'
s Days Payable Range Over the Past 10 Years
Min: 104.94 Med: 196.44 Max: 321.5
Current: 111.73
During the past 13 years, Dyadic International's highest Days Payable was 321.50. The lowest was 104.94. And the median was 196.44.
DYAI's Days Payable is ranked worse than 50.57% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs DYAI: 111.73
Dyadic International's Days Payable
declined
from Mar. 2025 (142.39) to Mar. 2026 (110.15).
It may suggest that Dyadic Internationalaccelerated paying its suppliers.
Dyadic International Days Payable Related Terms
Dyadic International Days Payable Historical Data
* Premium members only.
The historical data trend for Dyadic International's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dyadic International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's Days Payable distribution charts can be found below:
* The bar in red indicates where Dyadic International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Dyadic International's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International (DYAI) has a Days Payable of 110.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dyadic International and its competitors. This is 44% below median its historical median of 196.44. Over the past decade, Dyadic International's Days Payable has ranged from 104.94 to 321.50. According to the industry distribution chart, Dyadic International ranks #355 out of 702 companies in the Biotechnology industry, placing it in the top 50.6%.
Is Dyadic International's Days Payable too high?
Dyadic International's current Days Payable of 110.15 is 44% below median its 10-year median of 196.44. Over the past 10 years, this metric has ranged from a low of 104.94 to a high of 321.50. The Biotechnology industry median Days Payable is 113.10. Dyadic International's value of 110.15 is 2.6% below this industry median. Based on the distribution chart, Dyadic International ranks #355 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dyadic International has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's Days Payable compare to GRDX and TVGN?
According to the Biotechnology industry distribution chart, Dyadic International ranks #355 out of 702 companies for Days Payable. This places Dyadic International in the lower half of its industry. The industry median Days Payable is 113.10. Dyadic International's value of 110.15 is 2.6% below this benchmark. Historically, Dyadic International's own Days Payable has ranged from 104.94 to 321.50 over the past decade. While the company's 10-year median is 196.44 vs. the industry median of 113.10, Dyadic International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dyadic International's current Days Payable of 110.15 is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dyadic International and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dyadic International's current Days Payable is 110.15, which is 44% below median its own 10-year median of 196.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.74, compared to a current price of $1.47 — trading 98.6% above its estimated fair value. The current Days Payable is 110.15, which is 44% below median its 10-year median of 196.44 and 2.6% below the Biotechnology industry median of 113.10. Dyadic International's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Dyadic International (DYAI), the current Days Payable is 110.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be overvalued.
The current stock price of $1.47 is trading 98.6% above its estimated GF Value™ of $0.74.
GuruFocus considers Dyadic International to be Significantly Overvalued.
Key valuation signals for DYAI:
Days Payable: 110.15 (44% below median its 10-year median of 196.44)
GF Value™: $0.74 vs. price of $1.47 (98.6% above fair value)
Industry Position: 2.6% below the Biotechnology median (#355 of 702)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
37GF Score
Get the complete analysis for DYAI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
